Arcutis Biotherapeutics, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 1 | -$0.72 | -$0.66 | -$0.69 |
| Q2 2024 | 1 | -$0.54 | -$0.50 | -$0.52 |
| Q3 2024 | 1 | -$0.44 | -$0.40 | -$0.42 |
| Q4 2024 | 4 | -$0.32 | -$0.22 | -$0.28 |
| Q1 2025 | 2 | -$0.37 | -$0.30 | -$0.34 |
| Q2 2025 | 1 | -$0.29 | -$0.27 | -$0.28 |
| Q3 2025 | 1 | -$0.25 | -$0.23 | -$0.24 |
| Q4 2025 | 1 | -$0.26 | -$0.24 | -$0.25 |
Arcutis Biotherapeutics, Inc. Earnings Date And Information
Arcutis Biotherapeutics, Inc. last posted its earnings results on Wednesday, November 6th, 2024. The company reported $-0.33 earnings per share for the quarter, topping analysts' consensus estimates of $-0.42 by $0.09. The company had revenue of 44.76 M for the quarter and had revenue of 59.61 M for the year. Arcutis Biotherapeutics, Inc. has generated $-4 earnings per share over the last year ($-3.78 diluted earnings per share) and currently has a price-to-earnings ratio of -6.45. Arcutis Biotherapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, February 25th, 2025 based on prior year's report dates.
Arcutis Biotherapeutics, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/06/2024 | Q3 2024 | -$0.42 | -$0.33 | 0.09 | $37.62 M | $44.76 M |
| 08/14/2024 | Q2 2024 | -$0.48 | -$0.42 | 0.06 | $29.09 M | $30.86 M |
| 07/24/2024 | Q1 2024 | -$0.32 | $49.57 M | |||
| 02/27/2024 | Q4 2023 | -$0.65 | -$0.72 | -0.07 | $13.53 M | |
| 11/03/2023 | Q3 2023 | -$0.90 | -$0.73 | 0.17 | $32.91 M | $38.11 M |
| 08/08/2023 | Q2 2023 | -$1.22 | -$1.16 | 0.06 | $4.60 M | $5.19 M |
| 05/09/2023 | Q1 2023 | -$1.30 | -$1.30 | 0 | $2.78 M | |
| 02/28/2023 | Q4 2022 | -$1.37 | -$1.24 | 0.13 | $2.96 M | |
| 11/08/2022 | Q3 2022 | -$1.54 | -$1.94 | -0.4 | $614,286 | $725,000 |
| 08/04/2022 | Q2 2022 | -$1.38 | -$1.34 | 0.04 | $0 | |
| 05/05/2022 | Q1 2022 | -$1.42 | -$1.31 | 0.11 | $0 | |
| 03/03/2022 | Q4 2021 | -$1.42 | $0 | |||
| 11/04/2021 | Q3 2021 | -$1.09 | -$1.14 | -0.05 | $0 | |
| 08/05/2021 | Q2 2021 | -$0.91 | -$0.84 | 0.07 | $0 | |
| 05/06/2021 | Q1 2021 | -$0.76 | $0 | |||
| 02/16/2021 | Q4 2020 | -$0.89 | -$0.79 | 0.1 | $0 | |
| 11/05/2020 | Q3 2020 | -$0.95 | -$1.01 | -0.06 | $0 | |
| 08/11/2020 | Q2 2020 | -$0.84 | -$0.94 | -0.1 | $0 | |
| 05/12/2020 | Q1 2020 | -$0.92 | -$0.74 | 0.18 | $0 | |
| 03/19/2020 | Q4 2019 | -$0.33 | $0 |
Arcutis Biotherapeutics, Inc. Earnings: Frequently Asked Questions
-
When is Arcutis Biotherapeutics, Inc.'s earnings date?
Arcutis Biotherapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, February 25th, 2025 based off last year's report dates.
-
Did Arcutis Biotherapeutics, Inc. beat their earnings estimates last quarter?
In the previous quarter, Arcutis Biotherapeutics, Inc. (:ARQT) reported $-0.33 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.42 by $0.09.
-
How can I listen to Arcutis Biotherapeutics, Inc.'s earnings conference call?
The conference call for Arcutis Biotherapeutics, Inc.'s latest earnings report can be listened to online.
-
How can I read Arcutis Biotherapeutics, Inc.'s conference call transcript?
The conference call transcript for Arcutis Biotherapeutics, Inc.'s latest earnings report can be read online.
-
How much revenue does Arcutis Biotherapeutics, Inc. generate each year?
Arcutis Biotherapeutics, Inc. (:ARQT) has a recorded annual revenue of $59.61 M.
-
How much profit does Arcutis Biotherapeutics, Inc. generate each year?
Arcutis Biotherapeutics, Inc. (:ARQT) has a recorded net income of $59.61 M. Arcutis Biotherapeutics, Inc. has generated $-3.78 earnings per share over the last four quarters.
-
What is Arcutis Biotherapeutics, Inc.'s price-to-earnings ratio?
Arcutis Biotherapeutics, Inc. (:ARQT) has a price-to-earnings ratio of -6.45 and price/earnings-to-growth ratio is -0.19.
